Promoting self-compassion meditation with intranasal oxytocin in borderline personality disorder: a pilot study

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Borderline personality disorder (BPD) is characterized by emotion dysregulation, interpersonal difficulties, and high levels of self-criticism, which may hinder engagement with compassion-based therapeutic practices.

Oxytocin has been proposed as a modulator of social-affective processes and may facilitate specific mechanisms involved in psychotherapy.

Who Took Part

The study group was 18 individuals.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

The individuals were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Neither the individuals nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Oxytocin group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Oxytocin study would be practical.

Compassion practice quality was assessed at baseline (T1) and endpoint (T5).

Endpoint differences were examined using ANCOVA models controlling for baseline values.

What Was Measured

Borderline personality disorder (BPD) is characterized by emotion dysregulation, interpersonal difficulties, and high levels of self-criticism, which may hinder engagement with compassion-based therapeutic practices.

Topics PubMed links to this paper include Oxytocin, Pilot Projects, Empathy, Borderline Personality Disorder, Meditation and Self Concept.

The authors tagged it with the keywords Compassion meditation, Intranasal oxytocin and Pilot study.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 18 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Psychiatry research), a journal based in Ireland.

More context: the Oxytocin compound page, all human trials.